2025-07-20 - Analysis Report
Okay, here's a report analyzing Transmedics Group Inc (TMDX) based on the data provided.

**Report on Transmedics Group Inc (TMDX)**

**1. Performance Overview and Relative Performance**

*   **Ticker:** TMDX
*   **Company:** Transmedics Group Inc (A medical technology company focused on organ preservation.)

**Key Performance Numbers:**

*   **Cumulative Return (TMDX):** 227.91%
*   **Cumulative Return (S&P 500/VOO):** 68.29%
*   **Absolute Performance Difference:** 159.6 (Max: 296.4, Min: -64.2)
*   **Relative Performance Difference:** 62.1 (Indicates current outperformance relative to the S&P 500 within its historical range)

**Analysis of Alpha and Beta:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
| ---------- | ------- | ----- | ------ | ---- | ------ |
| 2019-2021  | -4.0%   | 63.4% | -52.0% | 0.0  | 0.7    |
| 2020-2022  | 140.0%  | 68.3% | 138.0% | 0.1  | 2.1    |
| 2021-2023  | 95.0%   | 69.4% | 77.0%  | 0.2  | 2.7    |
| 2022-2024  | 147.0%  | 82.8% | 121.0% | 0.2  | 2.1    |
| 2023-2025  | 109.0%  | 82.8% | 60.0%  | 0.5  | 3.7    |

*   **CAGR:** The Compound Annual Growth Rate shows strong growth in recent periods (2020-2025). The high CAGR figures are impressive, reflecting substantial returns.
*   **MDD:** The Maximum Drawdown indicates significant downside risk.  MDD values around 60-80% suggest high volatility.
*   **Alpha:**  High positive Alpha values indicate significant outperformance relative to the benchmark (S&P 500).  This is a very positive sign.
*   **Beta:** Beta values consistently above 1 suggest higher volatility than the market. The rising Beta in recent periods (especially 2023-2025) indicates increasing sensitivity to market movements.
*   **Cap(B):**  Market Capitalization(Billions)
**Summary:** TMDX has significantly outperformed the S&P 500. However, the high MDD and Beta indicate a higher risk profile. The strong Alpha figures are a major positive.

**2. Recent Price Action**

*   **Current Price:** $109.88
*   **Previous Close:** $112.52
*   **Change:** -$2.35
*   **5-day Moving Average:** $113.66
*   **20-day Moving Average:** $123.76
*   **60-day Moving Average:** $119.98

**Analysis:**

*   The stock price has recently decreased (negative change).
*   The current price is below all three moving averages (5-day, 20-day, and 60-day), suggesting a short-term downtrend.  The 5-day MA is below the 20-day MA, which is also below the 60-day MA, further reinforcing the downtrend signal.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3399 (Low Risk)
*   **RSI:** 25.90 (Oversold)
*   **PPO:** -1.87 (Negative momentum)
*   **Hybrid Signal:** cash_69%_Sell 0.7% of holdings (4 shares - Caution - MRI:0.35)
*   **Recent (20-day) Relative Performance Change:** -0.9 (Short-term decline)
*   **Expected Return:** 59.6% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** The low MRI suggests a low-risk environment overall.
*   **RSI:** The RSI is in oversold territory, which could indicate a potential buying opportunity in the short term.
*   **PPO:** The negative PPO confirms the downward momentum.
*   **Hybrid Signal:** The signal recommends a relatively high cash position (69%) and a small reduction in holdings, suggesting a cautious approach.
*   **Recent Price Change Reflection:** The recent price change of -$2.35 is a notable drop, contributing to the negative momentum and oversold RSI. This could be a reaction to recent news or events (see section 4).
*   **Expected Return:** The high expected return (59.6%) suggests strong confidence in the company's long-term prospects, anticipating significant outperformance compared to the S&P 500.

**4. Recent News & Significant Events**

*   **[2025-07-20]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-16]:** Analyst discussions on performance and outlook.
*   **[2025-07-17]:** Notable stock volatility.
*   **[2025-07-19]:** Experts highlighting risks and opportunities.

**Analysis:**

*   The news indicates significant activity and volatility surrounding TMDX. The analyst discussions and expert opinions suggest a mixed outlook, with both risks and opportunities present.  The mention of business developments and regulatory changes could be contributing to the recent price volatility.

**5. Recent Earnings Analysis**

| Date       | EPS  | Expected EPS |
| ---------- | ---- | ------------ |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |
| 2024-04-30 | 0.35 | 0.03256      |

**Analysis:**

*   TMDX has consistently exceeded EPS expectations in the most recent quarters, notably with a significant beat in 2025-05-08 (0.7 vs 0.29). This is a strong positive sign, suggesting the company is performing well financially.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue | Profit Margin |
| ---------- | ------- | ------------- |
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |
| 2024-03-31 | $0.10B  | 61.91%        |

**Capital and Profitability**

| Quarter    | Equity  | ROE   |
| ---------- | ------- | ----- |
| 2025-03-31 | $0.27B  | 9.64% |
| 2024-12-31 | $0.23B  | 3.00% |
| 2024-09-30 | $0.21B  | 2.01% |
| 2024-06-30 | $0.19B  | 6.42% |
| 2024-03-31 | $0.16B  | 7.65% |

**Analysis:**

*   **Revenue:** Revenue has been steadily increasing, indicating growth in the company's business.
*   **Profit Margin:** The profit margins are exceptionally high and relatively stable, suggesting strong operational efficiency and pricing power.
*   **Equity:** Equity has been consistently increasing, indicating a strengthening financial position.
*   **ROE:** Return on Equity (ROE) is fluctuating, but generally trending upwards, particularly in the most recent quarter. This suggests improving profitability relative to shareholder equity.

**7. Overall Summary and Recommendation**

**Summary:**

Transmedics Group Inc (TMDX) presents a mixed picture. The company has demonstrated significant outperformance compared to the S&P 500, as reflected in its high cumulative return and positive Alpha. Recent earnings have consistently exceeded expectations, and financial metrics like revenue, profit margin, equity, and ROE show positive trends. However, the stock exhibits high volatility (high MDD and Beta) and has recently experienced a price decline, with technical indicators suggesting a short-term downtrend (price below moving averages, negative PPO, oversold RSI). Recent news highlights significant activity and potential risks alongside opportunities.

**Recommendation:**

Given the high volatility and recent price decline, a **cautious approach** is warranted. The high expected return and strong financial performance suggest long-term potential, but investors should be aware of the risks.

*   **For existing holders:** Consider the hybrid signal's recommendation to hold a high cash position and make a minor reduction in holdings.
*   **For potential investors:** The oversold RSI might present a buying opportunity, but it's prudent to wait for a confirmation of a trend reversal before initiating a position. Conduct thorough due diligence and carefully monitor news and company announcements. Small, incremental investments may be considered to capitalize on potential rebounds while managing risk.
